Monitoring the safety of ESAs involves regular hemoglobin level assessments and adjusting doses accordingly. It is essential to keep hemoglobin levels within a target range to minimize the risk of adverse effects. Additionally, patients receiving ESA therapy should be monitored for signs of cardiovascular complications, hypertension, and any unusual symptoms that could indicate toxic effects.
